Chemical compound
 ;templatestyles src="Infobox drug/styles.css"/ ;
 ||{{#switch: |mab |combo |vaccine= [Email] (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate|mab=ethyl [Email] (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate|=
}}|[[Category:Infobox drug articles with contradicting parameter input| ]]}}{{#if:|{{#if:noneInvestigational drug|[[Category:Infobox drug articles with contradicting parameter input|Endogenous]]}}}}{{#if:88321-09-9 ||[[Category:Chemical articles without CAS registry number|*]]}}{{#if:101381
 ||[[Category:Drugs with no legal status]]}}{{#if:{{#ifeq:{{lc:}} ||[[Category:Infobox drug articles without vaccine target]]}}{{#if: |[[Category:Drug has EMA link]]}}{{#if: |[[Category:Chemicals having QID set|*]]}}{{#if: |[[Category:Chemicals (indexed) having QID set|*]]}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to verified fields]]
}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to watched fields]]
Aloxistatin (loxistatin, E-64d, EST) is a drug which acts as a [[cysteine protease]] inhibitor and has [[anticoagulant]] effects. It is a synthetic analogue of [[E-64]], a natural product derived from fungi. It was researched for the treatment of [[muscular dystrophy]] but was not successful in human [[clinical trial]]s, though it has continued to be investigated for treatment of [[spinal cord injury]], [[stroke]] and [[Alzheimer's disease]]. 
Aloxistatin also shows [[antiviral]] effects. Studies have shown it can inhibit [[cathepsin L]], a protein believed to play a role in [[SARS-CoV-2]] cellular entry. In a laboratory study using SARS-CoV-2 pseudovirions, aloxistatin was able to reduce [[viral entry]] into cells by approximately 92%.
References.
 ;templatestyles src="Reflist/styles.css" / ;
[[Category:Anticoagulants]]
[[Category:Ethyl esters]]
[[Category:Epoxides]]
[[Category:Carboxamides]]
[[Category:Dipeptides]]
[[Category:Experimental antiviral drugs]]
[[Category:COVID-19 drug development]]